Answers are grounded in this paper and cite their sources.
Experimental findings demonstrate that both dendritic cell subsets activate CD8+ T cells, suggesting flexible vaccine design.
Two distinct developmental pathways are driving the formation of myeloid- and lymphoid-related dendritic cells (DC) which differ in anatomical localization and phenotype. In terms of function, it has been hypothesized that only the myeloid-related CD8(-) DC are able to initiate immune responses, whereas the lymphoid-related CD8(+) DC have been suggested to induce tolerance. Here we show that both subsets activate CD8(+) T cells in vitro and induce protective anti-viral CTL responses in vivo. Thus, vaccine strategies using peptide-pulsed DC do not have to take into account DC subsets for priming.
No takes yet. Share an insight, caveat, or question.
Ruedl et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: